Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Abstract

BACKGROUND First-line agents approved in the United States for treatment of relapsing multiple sclerosis (MS) include intramuscular interferon beta (IFNbeta)-1a, subcutaneous (SC) IFNbeta-1a, SC IFNbeta-1b, and SC glatiramer acetate. Intravenous mitoxantrone is the only agent approved for secondary progressive MS, progressive relapsing MS, and worsening… (More)
DOI: 10.1185/03007990802329959

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.